Mucormycosis, a serious and rare fungal infection, has recently been reported in COVID-19 patients worldwide. This study aims to map all the emerging evidence on the COVID-19-associated mucormycosis (CAM) with a special focus on clinical presentation, treatment modalities, and patient outcomes. An extensive literature search was performed in MEDLINE (Ovid), Embase (Ovid), Cochrane COVID-19 Study Register, and WHO COVID-19 database till 9 June 2021. The primary outcome was to summarize the clinical presentation, treatment modalities, and patient outcomes of CAM. Data were summarized using descriptive statistics and presented in tabular form. This evidence mapping was based on a total of 167 CAM patients with a mean age of 51 ± 14.62 years, and 56.28% of them were male. Diabetes mellitus (73.65% (n = 123)), hypertension (22.75% (n = 38)), and renal failure (10.77% (n = 18)) were the most common co-morbidities among CAM patients. The most common symptoms observed in CAM patients were facial pain, ptosis, proptosis, visual acuity, and vision loss. Survival was higher in patients who underwent both medical and surgical management (64.96%). Overall mortality among CAM patients was found to be 38.32%. In conclusion, this study found a high incidence of CAM with a high mortality rate. Optimal glycemic control and early identification of mucormycosis should be the priority to reduce the morbidity and mortality related to CAM.

Czech National Centre for Evidence Based Healthcare and Knowledge Translation Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Kamenice 5 62500 Brno Czech Republic

Department of Nursing and Midwifery Faculty of Medicine Masaryk University Kamenice 5 62500 Brno Czech Republic

Department of Pharmacology School of Pharmaceutical Education and Research Jamia Hamdard New Delhi 110062 India

Department of Public Health Faculty of Medicine Masaryk University Kamenice 5 62500 Brno Czech Republic

Independent Researcher New Delhi 110062 India

Zobrazit více v PubMed

WHO Coronavirus (COVID-19) Dashboard. [(accessed on 22 September 2021)]. Available online: https://covid19.who.int/

Challen R., Brooks-Pollock E., Read J.M., Dyson L., Tsaneva-Atanasova K., Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched cohort study. BMJ. 2021;372:n579. PubMed PMC

Vaidyanathan G. Coronavirus variants are spreading in India—What scientists know so far. Nature. 2021;593:321–322. doi: 10.1038/d41586-021-01274-7. PubMed DOI

Miller I.F., Becker A.D., Grenfell B.T., Metcalf C.J.E. Disease and healthcare burden of COVID-19 in the United States. Nat. Med. 2020;26:1212–1217. doi: 10.1038/s41591-020-0952-y. PubMed DOI

Hussain S., Baxi H., Jamali M.C., Nisar N., Hussain M.S. Burden of diabetes mellitus and its impact on COVID-19 patients: A meta-analysis of real-world evidence. Diabetes Metab. Syndr. Clin. Res. Rev. 2020;14:1595–1602. doi: 10.1016/j.dsx.2020.08.014. PubMed DOI PMC

Ssentongo P., Ssentongo A.E., Heilbrunn E.S., Ba D.M., Chinchilli V.M. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS ONE. 2020;15:e0238215. doi: 10.1371/journal.pone.0238215. PubMed DOI PMC

Tian W., Jiang W., Yao J., Nicholson C.J., Li R., Sigurslid H., Wooster L., Rotter J.I., Guo X., Malhotra R. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J. Med. Virol. 2020;92:1875–1883. doi: 10.1002/jmv.26050. PubMed DOI PMC

Liu J., Li S., Liu J., Liang B., Wang X., Wang H., Li W., Tong Q., Yi J., Zhao L., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763. PubMed DOI PMC

Singh A.K., Majumdar S., Singh R., Misra A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective. Diabetes Metab. Syndr. Clin. Res. Rev. 2020;14:971–978. doi: 10.1016/j.dsx.2020.06.054. PubMed DOI PMC

Ritchie A.I., Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: A double-edged sword? Lancet. 2020;395:1111. doi: 10.1016/S0140-6736(20)30691-7. PubMed DOI PMC

Chen X., Liao B., Cheng L., Peng X., Xu X., Li Y., Hu T., Li J., Zhou X., Ren B. The microbial co-infection in COVID-19. Appl. Microbiol. Biotechnol. 2020:1–9. doi: 10.1007/s00253-020-10814-6. PubMed DOI PMC

Feldman C., Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia. 2021;13:1–15. doi: 10.1186/s41479-021-00083-w. PubMed DOI PMC

Abdoli A. Helminths and COVID-19 Co-Infections: A Neglected Critical Challenge. ACS Pharmacol. Transl. Sci. 2020;3:1039–1041. doi: 10.1021/acsptsci.0c00141. PubMed DOI PMC

Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: A systematic review and meta-analysis. J. Infect. 2020;81:266–275. doi: 10.1016/j.jinf.2020.05.046. PubMed DOI PMC

El-Herte R.I., Baban T.A., Kanj S.S. Mucormycosis: A review on environmental fungal spores and seasonal variation of human disease. Adv. Infect. Dis. 2012;2:76–81. doi: 10.4236/aid.2012.23012. DOI

Ibrahim A.S., Spellberg B., Walsh T.J., Kontoyiannis D.P. Pathogenesis of mucormycosis. Clin. Infect. Dis. 2012;54:S16–S22. doi: 10.1093/cid/cir865. PubMed DOI PMC

Wali U., Balkhair A., Al-Mujaini A. Cerebro-rhino orbital mucormycosis: An update. J. Infect. Public Health. 2012;5:116–126. doi: 10.1016/j.jiph.2012.01.003. PubMed DOI

Jeong W., Keighley C., Wolfe R., Lee W.L., Slavin M., Kong D.C., Chen S.C.-A. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 2019;25:26–34. doi: 10.1016/j.cmi.2018.07.011. PubMed DOI

Petrikkos G., Skiada A., Lortholary O., Roilides E., Walsh T.J., Kontoyiannis D.P. Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Dis. 2012;54:S23–S34. doi: 10.1093/cid/cir866. PubMed DOI

Centers for Disease Control and Prevention Mucormycosis Statistics. [(accessed on 10 June 2021)]; Available online: https://www.cdc.gov/fungal/diseases/mucormycosis/statistics.html.

Kontoyiannis D.P., Yang H., Song J., Kelkar S.S., Yang X., Azie N., Harrington R., Fan A., Lee E., Spalding J.R. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: A retrospective study. BMC Infect. Dis. 2016;16:1–6. doi: 10.1186/s12879-016-2023-z. PubMed DOI PMC

Heimann S.M., Vehreschild M.J., Cornely O.A., Heinz W.J., Grüner B., Silling G., Kessel J., Seidel D., Vehreschild J.J. Healthcare burden of probable and proven invasive mucormycosis: A multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016. J. Hosp. Infect. 2019;101:339–346. doi: 10.1016/j.jhin.2018.11.003. PubMed DOI

‘Black Fungus’ Declared an Epidemic in 4 States, 1 UT. [(accessed on 10 June 2021)]. Available online: http://timesofindia.indiatimes.com/articleshow/82804720.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst.

Singh A.K., Singh R., Joshi S.R., Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab. Syndr. Clin. Res. Rev. 2021;15:102146. doi: 10.1016/j.dsx.2021.05.019. PubMed DOI PMC

Pal R., Singh B., Bhadada S.K., Banerjee M., Bhogal R.S., Hage N., Kumar A. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses. 2021 doi: 10.1111/myc.13338. PubMed DOI PMC

Peters M., Godfrey C., McInerney P., Soares C.B., Khalil H., Parker D. The Joanna Briggs Institute Reviewers Manual 2015. Joanna Briggs Institute; Adelaide, Australia: 2015. Methodology for JBI scoping reviews; pp. 3–24.

Tricco A.C., Lillie E., Zarin W., O’Brien K.K., Colquhoun H., Levac D., Moher D., Perters M.D.J., Horsley T., Weeks L., et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann. Intern. Med. 2018;169:467–473. doi: 10.7326/M18-0850. PubMed DOI

Hussain S., Baxi H., Riad A., Kulgarova J., Licenik R., Klugar M. COVID-19 Associated Mucormycosis: Scoping Review Protocol. medRxiv. 2021 doi: 10.1101/2021.05.30.21258068. PubMed DOI PMC

Expert Search Coronavirus (Covid-19) 2019-nCoV on MEDLINE. 2020. [(accessed on 9 June 2021)]. Available online: https://tools.ovid.com/ovidtools/expertsearches.html.

Expert Search COVID-19 Embase 1974 to Present. 2020. [(accessed on 9 June 2021)]. Available online: https://tools.ovid.com/coronavirus/

Alekseyev K., Didenko L., Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J. Med. Cases. 2021;12:85. doi: 10.14740/jmc3637. PubMed DOI PMC

Arana C., Ramírez R.E.C., Xipell M., Casals J., Moreno A., Herrera S., Bodro M., Cofan F., Diekmann F., Esforzado N. Mucormycosis associated with covid19 in two kidney transplant patients. Transpl. Infect. Dis. 2021;23:e13652. doi: 10.1111/tid.13652. PubMed DOI PMC

Ashour M.M., Abdelaziz T.T., Ashour D.M., Askoura A., Saleh M.I., Mahmoud M.S. Imaging spectrum of acute invasive fungal rhino-orbital-cerebral sinusitis in COVID-19 patients: A case series and a review of literature. J. Neuroradiol. 2021;48:319–324. doi: 10.1016/j.neurad.2021.05.007. PubMed DOI PMC

Bayram N., Ozsaygılı C., Sav H., Tekin Y., Gundogan M., Pangal E., Cicek A., Özcan I. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Jpn. J. Ophthalmol. 2021;65:515–525. doi: 10.1007/s10384-021-00845-5. PubMed DOI PMC

Bellanger A.-P., Navellou J.-C., Lepiller Q., Brion A., Brunel A.-S., Millon L., Berceanu A. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infect. Dis. Now. 2021;51:633–635. PubMed PMC

Dallalzadeh L.O., Ozzello D.J., Liu C.Y., Kikkawa D.O., Korn B.S. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit. 2021:1–4. doi: 10.1080/01676830.2021.1903044. PubMed DOI

Do Monte Junior E.S., Dos Santos M.E.L., Ribeiro I.B., de Oliveira Luz G., Baba E.R., Hirsch B.S., Funari M.P., de Moura E.G.H. Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report. Clin. Endosc. 2020;53:746–749. doi: 10.5946/ce.2020.180. PubMed DOI PMC

El-Kholy N.A., Abd El-Fattah A.M., Khafagy Y.W. Invasive fungal sinusitis in post COVID-19 patients: A new clinical entity. Laryngoscope. 2021 doi: 10.1002/lary.29632. PubMed DOI PMC

Garg D., Muthu V., Sehgal I.S., Ramachandran R., Kaur H., Bhalla A., Puri G.D., Chakrabarti A., Agarwal R. Coronavirus disease (Covid-19) associated mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia. 2021;186:289–298. doi: 10.1007/s11046-021-00528-2. PubMed DOI PMC

Hanley B., Naresh K., Roufosse C., Nicholson A.G., Weir J., Cooke G.S., Thursz M., Manousou P., Corbett R., Goldin R., et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: A post-mortem study. Lancet Microbe. 2020;1:e245–e253. doi: 10.1016/S2666-5247(20)30115-4. PubMed DOI PMC

Johnson A.K., Ghazarian Z., Cendrowski K.D., Persichino J.G. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med. Mycol. Case Rep. 2021;32:64–67. doi: 10.1016/j.mmcr.2021.03.006. PubMed DOI PMC

Kanwar A., Jordan A., Olewiler S., Wehberg K., Cortes M., Jackson B.R. A fatal case of Rhizopus azygosporus pneumonia following COVID-19. J. Fungi. 2021;7:174. doi: 10.3390/jof7030174. PubMed DOI PMC

Karimi-Galougahi M., Arastou S., Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19) Int. Forum Allergy Rhinol. 2021;11:1029–1030. doi: 10.1002/alr.22785. PubMed DOI PMC

Khatri A., Chang K.-M., Berlinrut I., Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient—Case report and review of literature. J. Med. Mycol. 2021;31:101125. doi: 10.1016/j.mycmed.2021.101125. PubMed DOI PMC

Krishna D.S., Raj H., Kurup P., Juneja M. Maxillofacial Infections in Covid-19 Era—Actuality or the Unforeseen: 2 Case Reports. Indian J. Otolaryngol. Head Neck Surg. 2021:1–4. doi: 10.1007/s12070-021-02618-5. PubMed DOI PMC

Krishna V., Morjaria J., Jalandari R., Omar F., Kaul S. Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. IDCases. 2021;25:e01172. doi: 10.1016/j.idcr.2021.e01172. PubMed DOI PMC

Maini A., Tomar G., Khanna D., Kini Y., Mehta H., Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: A case report. Int. J. Surg. Case Rep. 2021;82:105957. doi: 10.1016/j.ijscr.2021.105957. PubMed DOI PMC

Mehta S., Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12:e10726. doi: 10.7759/cureus.10726. PubMed DOI PMC

Mekonnen Z.K., Ashraf D.C., Jankowski T., Grob S.R., Vagefi M.R., Kersten R.C., Simko J.P., Winn B.J. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthalmic Plast. Reconstr. Surg. 2021;37:e40. doi: 10.1097/IOP.0000000000001889. PubMed DOI PMC

Meshram H.S., Kute V.B., Chauhan S., Desai S. Mucormycosis in post-COVID-19 renal transplant patients: A lethal complication in follow-up. Transpl. Infect. Dis. 2021;23:e13663. doi: 10.1111/tid.13663. PubMed DOI PMC

Moorthy A., Gaikwad R., Krishna S., Hegde R., Kale P.G., Rao P.S., Haldipur D., Bonanthaya K. SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids—An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis. J. Maxillofac. Oral Surg. 2021;20:418–425. doi: 10.1007/s12663-021-01532-1. PubMed DOI PMC

Nehara H.R., Puri I., Singhal V., Ih S., Bishnoi B.R., Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India. Indian J. Med Microbiol. 2021;39:380–383. doi: 10.1016/j.ijmmb.2021.05.009. PubMed DOI PMC

Pakdel F., Ahmadikia K., Salehi M., Tabari A., Jafari R., Mehrparvar G., Rezaie Y., Rajaeih S., Alijani N., Barac A., et al. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicenter study from Iran. Mycoses. 2021;64:1238–1252. doi: 10.1111/myc.13334. PubMed DOI PMC

Pasero D., Sanna S., Liperi C., Piredda D., Branca G.P., Casadio L., Simeo R.S., Buselli A., Rizzo D., Bussu F., et al. A challenging complication following SARS-CoV-2 infection: A case of pulmonary mucormycosis. Infection. 2020:1–6. doi: 10.1007/s15010-020-01561-x. PubMed DOI PMC

Pauli M.A., de Melo Pereira L., Monteiro M.L., de Camargo A.R., Rabelo G.D. Painful palatal lesion in a COVID-19 patient. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2021;131:620–625. doi: 10.1016/j.oooo.2021.03.010. PubMed DOI PMC

Placik D.A., Taylor W.L., Wnuk N.M. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol. Case Rep. 2020;15:2378–2381. doi: 10.1016/j.radcr.2020.09.026. PubMed DOI PMC

Rabagliati R., Rodríguez N., Núñez C., Huete A., Bravo S., Garcia P. COVID-19–Associated Mold Infection in Critically Ill Patients, Chile. Emerg. Infect. Dis. 2021;27:1454. doi: 10.3201/eid2705.204412. PubMed DOI PMC

Rao R., Shetty A., Nagesh C. Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: Clinico-radiological features. Indian J. Ophthalmol. 2021;69:1627–1630. doi: 10.4103/ijo.IJO_1053_21. PubMed DOI PMC

Ravani S.A., Agrawal G.A., Leuva P.A., Modi P.H., Amin K.D. Rise of the phoenix: Mucormycosis in COVID-19 times. Indian J. Ophthalmol. 2021;69:1563–1568. PubMed PMC

Revannavar S.M., Supriya P., Samaga L., Vineeth V. COVID-19 triggering mucormycosis in a susceptible patient: A new phenomenon in the developing world? BMJ Case Rep. CP. 2021;14:e241663 PubMed PMC

Saldanha M., Reddy R., Vincent M.J. Of the article: Paranasal mucormycosis in COVID-19 patient. Indian J. Otolaryngol. Head Neck Surg. 2021:1–4. doi: 10.1007/s12070-021-02574-0. PubMed DOI PMC

Sarkar S., Gokhale T., Choudhury S.S., Deb A.K. COVID-19 and orbital mucormycosis. Indian J. Ophthalmol. 2021;69:1002. PubMed PMC

Sen M., Lahane S., Lahane T.P., Parekh R., Honavar S.G. Mucor in a viral land: A tale of two pathogens. Indian J. Ophthalmol. 2021;69:244. PubMed PMC

Veisi A., Bagheri A., Eshaghi M., Rikhtehgar M.H., Kanavi M.R., Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur. J. Ophthalmol. 2021:11206721211009450. doi: 10.1177/11206721211009450. PubMed DOI PMC

Waizel-Haiat S., Guerrero-Paz J.A., Sanchez-Hurtado L., Calleja-Alarcon S., Romero-Gutierrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus. 2021;13:e13163. PubMed PMC

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am. J. Emerg Med. 2021;42:264.e5–264.e8. doi: 10.1016/j.ajem.2020.09.032. PubMed DOI PMC

Zurl C., Hoenigl M., Schulz E., Hatzl S., Gorkiewicz G., Krause R., Eller P., Prattes J. Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy. J. Fungi. 2021;7:88. doi: 10.3390/jof7020088. PubMed DOI PMC

Mishra N., Mutya V.S.S., Thomas A., Rai G., Reddy B., Mohanan A.A. A case series of invasive mucormycosis in patients with COVID-19 infection. Int. J. Otorhinolaryngol. Head Neck Surg. 2021;7:867–870. doi: 10.18203/issn.2454-5929.ijohns20211583. DOI

Satish D., Joy D., Ross A. Balasubramanya. Mucormycosis co-infection associated with global COVID-19: A case series from India. Int. J. Otorhinolaryngol. Head Neck Surg. 2021;7:815–820. doi: 10.18203/issn.2454-5929.ijohns20211574. DOI

Evert K., Dienemann T., Brochhausen C., Lunz D., Lubnow M., Ritzka M., Keil F., Trummer M., Scheiter A., Salzberger B., et al. Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation. Virchows Arch. 2021;479:97–108. doi: 10.1007/s00428-020-03014-0. PubMed DOI PMC

Khan N., Gutierrez C.G., Martinez D.V., Proud K.C. A case report of COVID-19 associated pulmonary mucormycosis. Arch. Clin. Cases. 2021;7:46–51. doi: 10.22551/2020.28.0703.10172. PubMed DOI PMC

Hoang K., Abdo T., Reinersman J.M., Lu R., Higuita N.I.A. A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. Med. Mycol. Case Rep. 2020;29:22–24. doi: 10.1016/j.mmcr.2020.05.008. PubMed DOI PMC

Pan A.S., Srinath L. Mucormycosis in a patient with AIDS receiving systemic steroids. J. Am. Osteopath. Assoc. 2013;113:708–711. doi: 10.7556/jaoa.2013.037. PubMed DOI

India Accounts for 1 in 3 New Covid Cases Being Recorded. [(accessed on 10 June 2021)]. Available online: https://www.cnbc.com/2021/05/03/india-covid-crisis-charts-show-the-severity-of-the-second-wave.html.

Corzo-León D.E., Chora-Hernández L.D., Rodríguez-Zulueta A.P., Walsh T.J. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med. Mycol. 2018;56:29–43. doi: 10.1093/mmy/myx017. PubMed DOI

Erener S. Diabetes, infection risk and COVID-19. Mol. Metabolism. 2020;39:101044. doi: 10.1016/j.molmet.2020.101044. PubMed DOI PMC

Liu C., Feng X., Li Q., Wang Y., Li Q., Hua M. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine. 2016;86:100–109. doi: 10.1016/j.cyto.2016.06.028. PubMed DOI

Morales-Franco B., Nava-Villalba M., Medina-Guerrero E.O., Sánchez-Nuño Y.A., Davila-Villa P., Anaya-Ambriz E.J., Charles-Niño C.L. Host-Pathogen Molecular Factors Contribute to the Pathogenesis of Rhizopus spp. in Diabetes Mellitus. Curr. Trop. Med. Rep. 2021;8:6–17. doi: 10.1007/s40475-020-00222-1. PubMed DOI PMC

Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., Sein M., Sein T., Chiou C.C., Chu J.H., et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin. Infect. Dis. 2005;41:634–653. doi: 10.1086/432579. PubMed DOI

Uğurlu K., Selim S., Kopar A., Songu M. Rhino-orbital mucormycosis: Clinical findings and treatment outcomes of four cases. Turk. J. Ophthalmol. 2015;45:169. doi: 10.4274/tjo.82474. PubMed DOI PMC

Rhino-Orbital-Cerebral Mucormycosis. [(accessed on 10 June 2021)]. Available online: https://eyewiki.aao.org/Rhino-Orbital-Cerebral_Mucormycosis.

Patel A., Kaur H., Xess I., Michael J., Savio J., Rudramurthy S., Singh R., Shastri P., Umabala P., Sardana R., et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin. Microbiol. Infect. 2020;26:944.e9–944.e15. doi: 10.1016/j.cmi.2019.11.021. PubMed DOI

Skiada A., Lass-Floerl C., Klimko N., Ibrahim A., Roilides E., Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med. Mycol. 2018;56:S93–S101. doi: 10.1093/mmy/myx101. PubMed DOI PMC

Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU (MY-CO-VID) [(accessed on 25 June 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04368221.

Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis

COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors

COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping